Advanced Cell Technology to Present at the 2012 Bio International Convention and
the Clinical Outlooks for Regenerative Medicine Meeting
MARLBOROUGH, Mass., Jun 14, 2012 (BUSINESS WIRE) -- Advanced Cell Technology,
Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine,
announced today that the company is presenting at two upcoming conferences: the
2012 Bio International Convention and Clinical Outlooks for Regenerative Medicine
meeting, both in Boston, on Tuesday, June 19. The presentations will cover the
company's three ongoing clinical trials using human embryonic stem cell-derived
retinal pigment epithelial cells to treat macular degeneration, and other
programs.
Gary Rabin, chairman and CEO, will present at the 2012 Bio International
Convention on Tuesday, June 19 at 8:15 a.m. EDT, at the Boston Convention &
Exhibition Center.
Matthew Vincent, Ph.D., director of business development, will present at the
Clinical Outlooks for Regenerative Medicine meeting at 9:15 a.m. EDT on the same
date, at the Starr Center, Schepens Eye Research Institute, at 185 Cambridge
Street in Boston.
Both presentation slide decks will be available on the conference presentations
section of the ACT website.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc., is a biotechnology company applying cellular
technology in the field of regenerative medicine. For more information, visit
advancedcell.com.
Forward-Looking Statements
Statements in this news release regarding future financial and operating results,
future growth in research and development programs, potential applications of our
technology, opportunities for the company and any other statements about the
future expectations, beliefs, goals, plans, or prospects expressed by management
constitute forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Any statements that are not statements
of historical fact (including statements containing the words "will," "believes,"
"plans," "anticipates," "expects," "estimates," and similar expressions) should
also be considered to be forward-looking statements. There are a number of
important factors that could cause actual results or events to differ materially
from those indicated by such forward-looking statements, including: limited
operating history, need for future capital, risks inherent in the development and
commercialization of potential products, protection of our intellectual property,
and economic conditions generally. Additional information on potential factors
that could affect our results and other risks and uncertainties are detailed from
time to time in the company's periodic reports, including the report on Form 10-K
for the year ended December 31, 2011. Forward-looking statements are based on the
beliefs, opinions, and expectations of the company's management at the time they
are made, and the company does not assume any obligation to update its
forward-looking statements if those beliefs, opinions, expectations, or other
circumstances should change. Forward-looking statements are based on the beliefs,
opinions, and expectations of the company's management at the time they are made,
and the company does not assume any obligation to update its forward-looking
statements if those beliefs, opinions, expectations, or other circumstances
should change. There can be no assurance that the Company's clinical trials will
be successful.
SOURCE: Advanced Cell Technology, Inc.
Investors:
CEOcast, Inc.
James Young, 212-732-4300
or
Press:
ACT Corporate Communications
Bill Douglass, 646-450-3615
or
Russo Partners
Martina Schwarzkopf, Ph.D., 212-845-4292
or
Business Development:
ACT
Matthew Vincent, Ph.D., 508-756-1212, ext. 324
mvincent@advancedcell.com |
